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Study objective: To determine the local incidence and clinical consequences of myoma, after intraperi-
toneal dissemination via morcellation.
Materials and methods: An electronic search for laparoscopic myomectomies in the computer database of
the KK Women's and Children's Hospital (Singapore) and sarcomas or myomata with atypical features in
the National Cancer Registry (Singapore) was performed for a 10-year study period. The identiﬁed pa-
tients had their medical records were traced and their data were extracted and studied in detail.
Results: The incidence of unexpected diagnosis (i.e., variants, atypia, and malignancy) was 0.23%, and the
incidence of unexpected sarcoma was 0.10%. One of four patients who underwent a subsequent lapa-
rotomy had peritoneal dissemination. She unfortunately was also the only mortality in this study.
Conclusion: Laparoscopic surgery had proven beneﬁts over open surgery, although the dissemination of
unexpected malignancy and extrauterine seeding were major concerns. To date, morcellation in the
endobag or cutting the specimen using a knife or scissors may be alternative surgical techniques.
Copyright © 2016, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Background/Introduction
Power morcellation has become a gold standard technique and
is used in modern minimally invasive surgery (MIS) for hysterec-
tomy and myomectomy indicated for benign gynecological disease
(e.g., uterine ﬁbroids). However, it has a dire consequence if the
morcellated tissues are sarcomas or tumors with atypical features.
This study aimed to determine the local incidence and clinical
consequences of these tumors, after intraperitoneal dissemination
via morcellation.
Materials and methods
An electronic search for laparoscopic myomectomies and mor-
cellation was performed for a 10-year study period in KK Women's
and Children's Hospital (Singapore). A separate search in the Na-
tional Cancer Registry (Singapore) during the same period was
performed using the keywords: “leiomyosarcoma”, “smoothof interest.
nd Gynaecology, KKWomen's
9, Singapore.
rGynecologicEndoscopyandMinimall
nc-nd/4.0/).muscle tumor of uncertain malignant potential” (“STUMP”),
“endometrial stromal sarcoma”, “cellular leiomyoma”, and “atyp-
ical leiomyoma”. The identiﬁed patients who met the study criteria
(i.e., sarcomas or myomata with atypical features) and who were
operated on for a presumed benign leiomyoma via laparoscopy and
morcellation had their medical records traced and their data
extracted and studied in detail.Results
From 2004 to 2013 in our center, 3013 MIS myomectomies were
performed with the aid of morcellation. Seven patients were sub-
sequently diagnosed as having malignancy, leiomyoma variants, or
atypical lesions on histological examination (Table 1). This ﬁnding
represents an estimated 0.23% incidence of unexpected diagnosis
(i.e., variants, atypia, andmalignancy). The incidence of unexpected
sarcoma is 0.10%. The ages of patients ranged 32e52 years. Two
patients in their early 30s with atypical leiomyoma and cellular
leiomyoma were appreciatively younger. The lesion sizes were
variable, but all lesions were> 4 cm. There was a mix of solitary and
multiple lesions in all categories.
For all seven patients with an unexpected diagnosis, follow-up
procedures were offered to complete cancer staging and evaluatey InvasiveTherapy. PublishedbyElsevierTaiwanLLC. This isanopenaccessarticleunder theCC
Table 1
Detailed analysis of patients with an unexpected diagnosis, after power morcellation for suspected leiomyoma.
Patient Age (y) Dx Size of mass 1st Peritoneal
diagnosis
2nd Peritoneal
diagnosis
Clinical follow up
Dx Interval
(mo.)
Dx Interval
(mo)
Status Treatment Interval
(mo.)
1H 52 LMS Multiple,
largest ¼ 5.7 cm
d 14 Alive None 100
2Y 43 LMS 9 cm LMS 1 LMS 11 Deceased Chemotherapy &
radiotherapy
51
3L 42 STUMP Multiple,
largest ¼ 7
Declined
surgery
Alive None 80
4W 41 STUMP Multiple,
largest ¼ 12 cm
d 2 Alive None 10
5C 47 ESS Multiple,
largest ¼ 4.4 cm
d 1 Alive None 76
6W 35 AL 4.8 cm Nil Alive None 32
7L 32 CL Multiple,
largest ¼ 4.1 cm
Nil Alive None 62
AL¼ atypical leiomyoma; CL¼ cellular leiomyoma; Dx¼ diagnosis; ESS¼ endometrial stromal sarcoma; LMS¼ leiomyosarcoma; STUMP¼ smoothmuscle tumor of uncertain
malignant potential.
Table 2
Different studies reporting the incidence of unexpected sarcoma.
Study Year Incidence of unexpected
sarcoma (%)
Leibsohn et al12 1990 0.49
Parker et al13 1994 0.23
Seidman et al7 2012 0.27
Kho et al14 2014 0.09
Our study 2015 0.10
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was performed for three patients with cancer. One STUMP patient
declined surgery, whereas the other patient underwent a total
hysterectomy and bilateral salpingo-oophorectomy. Both patients
with cellular leiomyoma and atypical leiomyomawere not keen for
surgeries after discussion.
Discussion
Uterine myomata are the most common benign uterine
neoplasm and typically occur in the middle to late reproductive
years. Myomectomy, as an conservative management option, is the
primary treatment for symptomatic myomata. It is often requested,
even when there is no further desire for pregnancy because of so-
cial or religious reasons. Myomectomy is increasingly performed by
reproductive surgeons1,2 because myomata may contribute to
infertility and may be responsible for serious complications during
pregnancy.3 Since 1979, laparoscopic myomectomy has been per-
formed.4 It has gained importance over the years because laparo-
scopic surgeries reduce operative blood loss, is associated with less
of a hemoglobin drop, more patients are fully recuperated by Day
15, and it has fewer overall complications, compared to open
myomectomy.5 In addition, it is cosmetically more desirable and
appealing for younger women who have not had previous open
abdominal surgeries.
Power morcellation has advanced MIS and allows a greater
number of ﬁbroids and larger ﬁbroids to be removed laparoscopi-
cally. A power morcellator is a hollow cylindrical instrument that
penetrates the abdominal wall, with sharp cutting blades on its end
through which a grasper can be inserted to pull the myoma into the
cylinder to cut out extractable pieces. However, morcellation is
associated with the spreading of the cellular material of the mor-
cellated tissue. Loose ﬁbroid fragments may become infarcted,
necrotic, or parasitic and disseminated if they are left behind.6
Disseminated disease reportedly occurs in more than one-half of
patients.7 Of note, at least six of 3013 cases of myoma morcellation
in our study were associated with the subsequent development of
disseminated peritoneal leiomyomatosis. In the year 2013, we re-
ported a miniseries that was managed in our center.8 Of the four
patients who underwent a subsequent laparotomy, only one pa-
tient had peritoneal dissemination. She was unfortunately the only
mortality in our study with a survival of 51 months.
In addition, there is a concern of disseminating unexpected
malignancy with increased mortality.9,10 Morcellation is anindependent risk factor for tumor recurrence. It is prognostically
associated with a shorter disease-free interval and overall survival.
Only morcellation, size, and mitosis were signiﬁcant factors, based
on multivariate analysis.11 Unexpected diagnosis of variant leio-
myoma, atypia, andmalignancy occurred in 0.23% of patients with a
presumed preoperative diagnosis of benign uterine leiomyoma
who underwent morcellation in our study. The incidence of unex-
pected sarcoma was 0.10%. This rate was similar to the incidence
reported by Seidman et al7 but lower than the incidence quoted by
Leibsohn et al,12 Parker et al,13 and Kho et al14 (Table 2).
Uterine sarcomas are rare and represent approximately 7.8% of
all invasive uterine cancers locally (4.9% leiomyosarcomas; 2.9%
endometrial stromal sarcomas).15 They are aggressive tumors with
a high rate of recurrence.16 Moreover, there is no reliable preop-
erative diagnostic tools to differentiate uterine sarcomas from their
benign counterparts.17 Our 10-year data showed a local sarcoma
prevalence rate of 0.65% in all patients undergoing MIS or lapa-
rotomy hysterectomies and myomectomies. This is higher than the
unexpected postmorcellation sarcoma rate of 0.10%. This ﬁnding
demonstrates the importance of preoperative risk stratiﬁcation.
In a safety communication notice, the United States Food and
Drug Administration (Silver Spring, MD, USA) recently discouraged
the use of laparoscopic power morcellation during hysterectomy or
myomectomy for the treatment of women with uterine ﬁbroids.
One of the largest suppliers of the device subsequently suspended
its sale until the medical community redeﬁnes the role of morcel-
lation. Despite decades of experience, the understanding of the
short- and long-term sequelae of themorcellation is limited. Hence,
during preoperative counseling with patients who are undergoing
laparoscopic myomectomy and hysterectomy for which morcella-
tion is anticipated, it is imperative to include the possible risk of
recurrence at extrauterine locations, despite the surgeon's best
efforts, and possible dissemination of unexpected malignancy with
an associated increase in mortality.
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cons of dissemination of unexpected malignancy and extrauterine
seeding or whether banning the morcellation procedure will solve
the issue are hotly debated topics, especially in the world of gy-
necology endoscopy. Complete abandonment of power morcella-
tion will deprive many women from beneﬁting fromMIS surgeries.
While waiting for the development of more effective diagnostic
tools to differentiate between sarcomas and benign myoma,18
alternative treatment options (e.g., vaginal hysterectomy, abdom-
inal hysterectomy, laparoscopically assisted vaginal hysterectomy,
natural oriﬁces gynecological endoscopic surgeries) and their risks
and beneﬁts should be discussed with patients.
Morcellation in a specimen bag mayminimize the risk of spread
in the peritoneal cavity. However it requires signiﬁcant laparo-
scopic skills and experience. There are potential concerns such as
insufﬁcient bag size, reduced visualization, disruption of the mor-
cellator by the bag, and morcellation of the bag and surrounding
organs leading to visceral injuries. Further studies are required to
evaluate the safety and feasibility of this technique.
Conclusion
Laparoscopic surgery had proven beneﬁts over open surgery.
However, the concern of disseminating unexpected malignancy
raised a signiﬁcant issue. Informed consent is crucial at this
moment. Patients should be warned about an unexpected malig-
nancy that may spread and worsen the prognosis if power mor-
cellation is considered the best option for benign uterine ﬁbroids.
Alternative treatment options should be discussed.
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